FEMTRACE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FEMTRACE (FEMTRACE).
Estrogen receptor agonist; binds to estrogen receptors, modulating gene transcription and cellular proliferation in target tissues.
| Metabolism | Hepatic metabolism primarily via CYP3A4; also undergoes glucuronidation and sulfation. Metabolites include estrone and estriol. |
| Excretion | Primarily renal; ~40% as unchanged drug and glucuronide conjugates. Biliary/fecal elimination is minor (~10-15%). |
| Half-life | Terminal elimination half-life is approximately 12-14 hours, supporting once-daily dosing in clinical use. |
| Protein binding | Approximately 95% bound, primarily to albumin and sex hormone-binding globulin (SHBG). |
| Volume of Distribution | Vd approximately 0.8-1.2 L/kg, indicating distribution into total body water and some tissue binding. |
| Bioavailability | Oral: ~30-40% due to first-pass metabolism. Comparative routes (e.g., transdermal) are not applicable as this drug is oral only. |
| Onset of Action | Oral: 30-60 minutes for symptom relief (e.g., hot flashes). |
| Duration of Action | Oral: 24 hours, with steady-state achieved after 5-7 days. |
1 to 2 mg orally once daily; for testosterone replacement in adult males, 2 to 4 mg orally once daily.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment is recommended; use with caution in severe renal impairment. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment, use with caution and consider reduced doses. |
| Pediatric use | Not recommended for use in pediatric patients. |
| Geriatric use | Use with caution; consider lower starting doses due to increased risk of adverse effects such as fluid retention and cardiovascular events. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FEMTRACE (FEMTRACE).
| Breastfeeding | Estradiol is excreted in human breast milk; M/P ratio not established. May reduce milk production and quality. Use while breastfeeding is not recommended. |
| Teratogenic Risk | FEMTRACE (estradiol) is contraindicated in pregnancy. Use in first trimester associated with congenital anomalies (cardiovascular, limb defects). Second and third trimester fetal risks include urogenital abnormalities, neurodevelopmental effects. No adequate human studies; animal studies show teratogenicity. |
| Fetal Monitoring |
■ FDA Black Box Warning
Estrogen therapy increases the risk of endometrial cancer in women with an intact uterus. Unopposed estrogen use is associated with an increased risk of endometrial hyperplasia and carcinoma. Concomitant progestin therapy is recommended.
| Serious Effects |
Breast cancer (known, suspected, or history), estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, active DVT/PE, history of DVT/PE or arterial thromboembolic disease (e.g., stroke, MI), known protein C, protein S, or antithrombin deficiency, or other thrombophilic disorders, hepatic impairment or disease, known or suspected pregnancy.
| Precautions | Cardiovascular disorders (e.g., stroke, DVT, pulmonary embolism), breast cancer, dementia (increased risk in women aged ≥65 years), gallbladder disease, hypertriglyceridemia, hereditary angioedema, and exacerbation of endometriosis. |
Loading safety data…
| Monitor maternal blood pressure, blood glucose, liver function, and signs of thromboembolism. Fetal monitoring not indicated if appropriate contraception used; if exposure occurs, consider fetal echocardiography and detailed anatomy ultrasound. |
| Fertility Effects | Estradiol suppresses gonadotropins, inhibiting ovulation; may impair fertility during use. Effects are reversible upon discontinuation. |